This page shows the latest melanoma news and features for those working in and with pharma, biotech and healthcare.
other areas including adjuvant melanoma and bladder cancer.
This includes research into Seres’ phase 1b candidate SER-401, which is being investigated for its ability to improve the clinical outcomes of metastatic melanoma patients treated with currently-available immunotherapies.
Tecentriq, plus MEK inhibitor Cotellic (cobimetinib) and BRAF inhibitor Zelboraf (vemurafenib), has been backed for the treatment of BRAF V600 mutation-positive advanced melanoma patients. ... The FDA approval of this Tecentriq combination represents an
In addition to lung cancer, Merck’s drug is approved for a host of other cancer types, including in China for advanced melanoma.
The lead drug in that programme is NEO-PTC-01, a T-cell therapy targeting shares RAS oncogenes in solid tumours, initially heading for a clinical trial on metastatic melanoma patients
The trial included patients with non-small cell lung cancer, ovarian cancer, melanoma, breast cancer and colorectal cancer and all were heavily pre-treated with a median of three prior therapies.
More from news
Approximately 82 fully matching, plus 291 partially matching documents found.
In European patients, the average five-year relative survival rate was 83% for melanoma, 83% for prostate cancer, 82% for breast cancer and 57% for colon cancer.
targets of small cell lung cancer and melanoma in adults, while its licensing became embroiled in a royalties dispute.
BMS led the charge when Opdivo became the first in its class to gain approval (in metastatic melanoma in December 2014 in Japan), but Merck &Co’s Keytruda has emerged as
China’s millions of tobacco smokers make for a large market, which may be why BMS filed for approval in lung cancer treatment, rather than melanoma, the leading indication in other
The recent failed phase 3 trial of a combination of MSD’s monoclonal antibody Keytruda (pembrolizumab) and InCyte Corporation’s epacadostat in metastatic melanoma is a case in point he says.
More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.
Since its first approval in 2014 for the treatment of advanced melanoma with BRAF mutations, Keytruda has become a blockbuster immunotherapy as well as introducing a new standard-of-care for
Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma
McCudden has worked across a number of disease areas including hepatitis C, anticoagulation, Alzheimer's disease, women's health, melanoma and nicotine replacement therapy.
This includes the Colorado, US-based company's binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.
Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.
More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.
They will use the cash boost to enable a market launch in the UK and prepare for international expansion with the commercialisation of their new melanoma test AMBLor in the USA
One shining example of this can be found in the Melanoma Likes Me campaign from WPP in Australia:. ... Then, the creepy online persona ‘Melanoma’ – would ‘like’, ‘follow’ and comment, in real time.
In this recent episode of Impetus Digital‘s Fireside Chat series, I sit down with Peter Birch, General Manager (Asia Pacific) at MetaOptima Technologies &host of the “Talking HealthTech Podcast.” We discuss a whole range of topics, including
According to the largest study (to date) in different racial and ethnic populations across the US, there was no evidence to support the association of UV exposure and melanoma incidence in ... black or Hispanic populations – studies assessing the
and the response of uveal melanoma.
More from PMHub
Approximately 3 fully matching, plus 14 partially matching documents found.
We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...